ClinicalTrials.gg
RecruitingNCT07416058PHOENIXUpdated Oct 23, 2026

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

A Phase 2 interventional study of QL1706 (bispecific antibody targeting PD-1 and CLTA-4) in Lung Adenocarcinoma, sponsored by Guangdong Association of Clinical Trials. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Guangdong Association of Clinical Trials · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 23, 2026Now RecruitingFirst site in China+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 88 studies in Adenocarcinoma of Lung with a site in China — 38 open to participants now, 41 under way, 9 of them phase 3. Adenocarcinoma of Lung · China.

Planned enrollment
36th of 57
61 · median 69
Started
2026
with 5 others
Phase 2
25 of 88
6 open now
Primary completion
2027-12
later than 28 of 40 live
Registered
81st of 88
by date

Among the 88 studies in Adenocarcinoma of Lung with a site in China, this one is the 36th largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is one of 25 in phase 2, reaches primary completion later than 28 of the 40 other live ones, and was the 81st registered.

Adenocarcinoma of Lung

418 studies on the registry are indexed under Adenocarcinoma of Lung; 78 are open to participants now.

Browse Adenocarcinoma of Lung studies →

Open to participants now

38 of the 88 studies in Adenocarcinoma of Lung with a site in China are open now. Recruiting first, the newest first:

32 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 57 Adenocarcinoma of Lung studies recruiting now, 36 (63%) set no upper age limit and 10 (18%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Adenocarcinoma of Lung with a site in China, or all of them as a file.
02

Study summary

The goal of this Phase II clinical trial (The PHOENIX Study) is to evaluate if the combination of QL1706 (Iparomlimab and Tuvonralimab), bevacizumab, and chemotherapy can treat patients with TKI-refractory, driver-gene positive (e.g., EGFR, ALK, ROS1, RET, KRAS, BRAF, HER2), non-squamous non-small cell lung cancer (NSCLC) who have high PD-L1 expression (TPS ≥50%).

The main question[s] it aims to answer [is/are]:

Does the quadruple combination therapy improve the Objective Response Rate (ORR) compared to historical chemotherapy data? What are the secondary efficacy outcomes, including Progression-Free Survival (PFS) and Overall Survival (OS)?

If there is a comparison group: There is no concurrent control group (this is an open-label, multi-cohort study). Researchers will compare the treatment outcomes of the participants to historical control data (standard platinum-based chemotherapy) to see if the objective response rate (ORR) improves from a historical baseline of 29% to a target of 55%.

Participants will:

Receive induction therapy every 3 weeks for 4 cycles, consisting of intravenous infusions of QL1706, bevacizumab, pemetrexed, and platinum chemotherapy (cisplatin or carboplatin).

Receive maintenance therapy every 3 weeks with QL1706 and bevacizumab for up to 2 years or until disease progression.

Undergo regular tumor assessments (CT or MRI scans) to monitor disease status according to RECIST v1.1 criteria.

Provide blood samples for safety monitoring and potential biomarker analysis.

03

Conditions studied

  • Lung Adenocarcinoma

Keywords

  • PD-L1
  • CTLA-4
  • QL1706
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The study will enroll adult patients (aged 18-75 years) with confirmed locally advanced or NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR (19del, L858R); ALK, ROS1, RET fusions; KRAS G12C; BRAF V600; and exon 20 insertions. Patients must have disease progression following at least one line of TKI therapy and a 2-week is required for prior TKI therapy or chemotherapy. Prior immunotherapy is not permitted. tumor proportion score (TPS) ≥ 50%, as confirmed by central laboratory testing using the 22C3 or SP263 clone on fresh or (collected within 2 years). Patients must have an (ECOG) Performance Status of 0 or 1, and presence of at least one per (RECIST) Version 1.1.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with QL1706 or other /PD-L1/CTLA-4 antibodies, unless allowed by the protocol.
  • Untreated or symptomatic central nervous system (CNS) . Participants with previously treated, stable, and asymptomatic off for at least 2 weeks before first dose may be eligible.
  • History of severe allergic reactions or to monoclonal antibodies, platinum agents, pemetrexed, bevacizumab, or any of the study drugs.
  • cardiovascular disease, including but not limited to:
  • Uncontrolled hypertension despite optimal medical management
  • (NYHA) class III or IV heart failure
  • Unstable angina, myocardial infarction, or stroke within 6 months prior to enrollment
  • Significant arrhythmias requiring anti-arrhythmic therapy
  • Active or history of disease that has required systemic treatment in the past 2 years (e.g., with disease-modifying agents, corticosteroids, or drugs), except for conditions such as vitiligo, resolved childhood asthma/atopy, or hypothyroidism on stable replacement therapy.
  • Active infection requiring systemic therapy, including known active , , or (HIV) infection, unless well controlled according to protocol-defined criteria.
  • Significant hemoptysis (e.g., ≥ 2.5 mL of bright red blood) within 3 months prior to enrollment or any evidence of high-risk bleeding or coagulation disorder that would contraindicate bevacizumab.
  • Major surgery within 4 weeks before first dose of study treatment or anticipated need for major surgery during the study.
  • Pregnant or breastfeeding women.
  • Any other serious medical condition, uncontrolled intercurrent illness, psychiatric illness, or social circumstance that, in the opinion of the investigator, would compromise the participant's safety, interfere with study evaluations, or preclude .
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (estimated)

Study arms

  • Experimental
    Cohort 1 (EGFR) consists of patients with EGFR-positive

    Cohort 1 (EGFR) consists of patients with EGFR-positive non-small cell lung cancer (NSCLC) who have failed prior EGFR-tyrosine kinase inhibitor (TKI) therapy

    Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

  • Experimental
    Cohort 2 (ALK/ROS1/RET) includes patients with sensitive ALK, ROS1, or RET mutations

    Cohort 2 (ALK/ROS1/RET) includes patients with sensitive ALK, ROS1, or RET mutations who have progressed on prior TKI therapy targeting the respective driver oncogenes,

    Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

  • Experimental
    Cohort 3 (KRAS/BRAF/HER2) comprises patients with KRAS G12C, BRAF V600, or HER2 exon 20 insertions

    Cohort 3 (KRAS/BRAF/HER2) comprises patients with KRAS G12C, BRAF V600, or HER2 exon 20 insertions (20ins) (N=15) who have failed prior targeted therapy for these actionable driver mutations.

    Drug: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

Interventions

  • DrugQL1706 (bispecific antibody targeting PD-1 and CLTA-4)

    Drug page: Iparomlimab/TuvonralimabStudies of Iparomlimab/TuvonralimabIparomlimab/Tuvonralimab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All cohorts will receive the same treatment regimen in 3-week cycles.Participants will receive combination therapy, consisting of QL1706 (5.0 mg/kg, day 1), bevacizumab (7.5 mg/kg, days1), pemetrexed(500 mg/m², days1) and Platinum \[Cisplatin (75 mg/m²) or Carboplatin (AUC 5/mg/ml, up to 750 mg), Day 1\],intravenously every 3 weeks for four cycles in induction phase, followed by QL1706 (5.0 mg/kg, day 1) and bevacizumab (7.5 mg/kg, days1) every 3 weeks for up to 2 years or until disease progression

    Also known as: pemetrexed, Platinum, bevacizumab

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) per RECIST 1.1

    Objective Response Rate (ORR) is defined as the proportion of participants who achieve a best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1, as assessed by the investigator.

    Time frame: From first dose until disease progression or start of new anti-cancer therapy, up to approximately 24 months.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Progression-Free Survival (PFS) is defined as the time from randomization to the first documented disease progression per RECIST 1.1 or death from any cause, whichever occurs first, as assessed by the investigator.

    Time frame: From enrollment until disease progression or death, whichever occurs first, up to approximately 24 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 45 non-industry phase 2 interventional studies under Adenocarcinoma of Lung, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 73. This study's planned 20 months is below that.

Counting every sponsor, half of 53 studies reached it within 53 months; a quarter within 33 and three quarters within 71.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Apr 2026, on Oct 23, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2026
First posted
Feb 17, 2026
StartActual
Apr 30, 2026was Jan 2026
Primary completionEst.
Dec 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Guangdong Provincial People's Hospital · Guangzhou, China
  • Guangdong Provincial People's Hospital · Guangzhou, China
Oct 23, 2026
Start date
Jan 31, 2026→Apr 30, 2026 (actual)
Oct 23, 2026
Primary completion
Dec 31, 2027→Dec 30, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Guangdong Provincial People's Hospital · Guangzhou, China
    • Guangdong Provincial People's Hospital · Guangzhou, China
    Start date Jan 31, 2026→Apr 30, 2026 (now actual)
    Primary completion Dec 31, 2027→Dec 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07416058
Lead sponsor
Guangdong Association of Clinical Trials
Responsible party
Jin-Ji Yang (Chief Physician, Department of Medical Oncology, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Feb 17, 2026
Start date
Apr 30, 2026
Primary completion
Dec 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Hao Sun, Doctor
Contact
sunhao@gdph.org.cn
+86 16620178852

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iparomlimab/Tuvonralimab

Start the discussion